Bioceltix S.A. (WSE:BCX)
Poland · Delayed Price · Currency is PLN | Market Cap | 495.14M -10.9% |
| Revenue (ttm) | n/a |
| Net Income | -17.04M |
| EPS | -3.31 |
| Shares Out | 5.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,367 |
| Open | 87.50 |
| Previous Close | 87.90 |
| Day's Range | 87.50 - 94.50 |
| 52-Week Range | 70.00 - 116.80 |
| Beta | 0.91 |
| Analysts | Strong Buy |
| Price Target | 133.00 (0.0%) |
| Earnings Date | May 29, 2026 |
About Bioceltix
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was founded in 2016 and is headquartered in Wrocław, Poland. [Read more]
Financial Performance
Financial StatementsNews
Bioceltix Quarterly report: Q1 2026
Bioceltix has published its Q1 2026 quarterly earnings report on May 29, 2026.
Bioceltix Annual report: Q4 2025
Bioceltix has published its Q4 2025 annual report on April 28, 2026.
Bioceltix Slides: Company presentation
Bioceltix has posted slides in relation to its latest quarterly earnings report, which was published on March 31, 2026.
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
NEW YORK--(BUSINESS WIRE)---- $BBN--Today, BlackRock Resources & Commodities Strategy Trust (NYSE: BCX), BlackRock Enhanced Equity Dividend Trust (NYSE: BDJ), BlackRock Energy and Resources Trust (NYS...
Bioceltix Quarterly report: Q3 2025
Bioceltix has published its Q3 2025 quarterly earnings report on November 28, 2025.
5 High Yield CEFs With Steep Discounts Right Now
Closed-end funds (CEFs) are the last bargains left on the board. CEFs are often confused with mutual funds and ETFs, but they are different because they often trade at discounts to their net asset val...
Bioceltix Quarterly report: Q2 2025
Bioceltix has published its Q2 2025 quarterly earnings report on September 30, 2025.
Certain BlackRock Sector Equity Closed-End Funds Announce Updates to Investment Objectives and Principal Investment Strategies
NEW YORK--(BUSINESS WIRE)---- $BCX--The BlackRock Sector Equity Closed End Funds (CEFs) listed below (the “Funds”) announced today that each Fund's Board of Trustees (the "Board") has approved the fol...
Certain BlackRock Funds Announce Final Results of Tender Offers
NEW YORK--(BUSINESS WIRE)---- $BCX--The BlackRock closed-end funds (the “Funds”) listed below announced today the final results of each Fund's tender offer (each, a “Tender Offer”) for up to 2.5% of i...
Certain BlackRock Funds Announce Expiration and Preliminary Results of Tender Offers
NEW YORK--(BUSINESS WIRE)---- $BCX--The BlackRock closed-end funds (the “Funds”) listed below announced today the expiration and preliminary results of each Fund's tender offer (each, a “Tender Offer”...
BlackRock Announces Distribution Increases for Certain Closed-End Funds
NEW YORK--(BUSINESS WIRE)---- $BCX--Today, the BlackRock closed-end funds listed below (each a “Fund,” and collectively the “Funds”) have announced changes to their monthly distribution amounts per sh...
These 15 Dividends Could Be Great In 2025
With stocks back in “climb” mode (at least for now!), it could seem like a good time to look for a hedge against the next downturn.
CORRECTING and REPLACING BlackRock Closed-End Fund Share Repurchase Program Update
NEW YORK--(BUSINESS WIRE)--Please replace the release dated April 11, 2023, with the following corrected version due to changes in the table, "Summary of share repurchase activity since Repurchase Pro...